Company profile
Taysha Gene Therapies, Inc.
NASDAQ: TSHA · Healthcare · Biotechnology
#637 of 1,422 Healthcare companies by revenue63rd-percentile growth
EA Score
48DFH 51DQ 37GM 55SS 59
v0.1 · 65/100 weight · provisional
↑ Altman-Z, market scale · ↓ growth stability, disclosure history
Methodology →Revenue TTM
$5.5M
Rev growth YoY (TTM)
-32.3%
Net income (FY)
-$109.0M
Employees
99
as of 2026-08-09
Market cap
$2.1B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$9.8M$9.8M2025
Net income-$109.0M-$109.0M2025
Operating income-$110.5M-$110.5M2025
Total assets$343.3M$343.3M2025
Liabilities$96.4M$96.4M2025
Equity$246.9M$246.9M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Taysha Gene Therapies, Inc.’s revenue?
Taysha Gene Therapies, Inc. booked $9.8M in FY2025 revenue, growing 17% year over year — faster than most Healthcare companies we track, at a -1115.3% net margin.
Peers · Healthcare
Janux Therapeutics, Inc.54DSyros Pharmaceuticals, Inc.——Stablecoin Development Corp.44DCalithera Biosciences, Inc.——Precigen, Inc.44DDelivra Health Brands Inc.55CNeighbors
Dallas →Key facts
CEOSean Nolan
SectorHealthcare
IndustryBiotechnology
HeadquartersDallas, TX
ExchangeNASDAQ: TSHA
Employees99
IPO date2020-09-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.